ClinicalTrials.gg
CompletedNCT01693601PRIMEUpdated Oct 31, 2023Results posted

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

A Phase 1/2 interventional study of Panobinostat and Ruxolitinib in Myelofibrosis, sponsored by John Mascarenhas. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-31.

Sponsored by John Mascarenhas · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
39th of 50
15 · median 45
Started
2013
with 4 others
Phase 1/2
8 of 50
2 open now
Registered
14th of 50
by date
Lead sponsor
3 of 50
John Mascarenhas

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 39th largest by enrollment, is one of 5 that started in 2013, is one of 8 in phase 1/2, and was the 14th registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This is a single-center, single arm, dose finding study to assess safety and tolerability of the oral combination of Panobinostat and Ruxolitinib in patients with myelofibrosis (MF) in chronic and accelerated phase.

Read the detailed description

Phase I/II open label, single institution, combination therapy trial of induction Ruxolitinib followed by combination with Panobinostat in dose escalation cohorts with a primary endpoint of determining the safety and tolerability of combination therapy in patients with myelofibrosis (MF) in chronic and accelerated phase. A 3+3standard dose escalation scheme will be employed and the occurrence of dose limiting toxicities (DLTs) will be captured and the occurrence of such events will determine dose cohort escalation by predetermined and established rules. In addition to establishing the DLTs, maximally tolerated dose (MTD), and recommended phase II dose (RPTD) in the phase I portion of this trial, exploratory biomarkers will be evaluated within phase I as well. Pharmacodynamics and exploratory genetic and epigenetic biomarkers will be explored as predictors of response to therapy. The RPTD cohort will be expanded to incorporate a total of 22 patients, including 6 from phase I, in order to assess clinical response as assessed by International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) as a primary endpoint for the phase II portion of this trial.

03

Conditions studied

  • Myelofibrosis

Browse trials for

Keywords

  • Myelofibrosis
  • Panobinostat
  • Ruxolitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged ≥ 18 years old
  • Ability to provide written obtained prior to participation in the study and any related procedures being performed
  • Intermediate-2 and higher by IWG-MRT Post PV/ET MF and PMF patients either in

    1. Chronic Phase (MF-CP)
    2. Accelerated Phase (MF-AP)
  • Patients must meet the following laboratory criteria:

    1. ≥ .750 x 109/L
    2. ≥ 75 x 109/L
    3. Creatinine ≤ 1.5 x ,
    4. and ALT ≤ 2.5 x ULN
    5. Serum ≤ 1.5 x ULN (unless Gilbert's syndrome and evidence of hemolysis)
    6. Serum potassium ≥ LLN
    7. Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN,
    8. Serum magnesium ≥ LLN
    9. Serum phosphorus ≥ LLN
    10. Free T4 within normal limits
  • Performance Status of ≤ 3
  • Any prior therapy with JAK2-TKI, hypomethylating agents, HDACI, mTORi, or iMiDs is allowed as long as it is greater than 3 weeks since last dose of administration and in the case of a JAK2-TKI or HDACI that discontinuation was not due to non-hematologic drug toxicity. An exception to this criteria are patients currently on at least 10mg BID of ruxolitinib for greater than 3 months and who have not shown an optimal response (i.e. without 50% reduction in palpable splenomegaly or 50% reduction in symptom burden). With a reduction of ruxolitinib to 10mg BID these patients may enter onto the study without stopping ruxolitinib

Exclusion criteria

Exclusion Criteria:

  • Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first PANOBINOSTAT treatment.
  • Impaired cardiac function or cardiac diseases, including any one of the following:

    1. With permanent cardiac pacemaker
    2. Resting bradycardia defined as \<50 beats per minute
    3. >450 msec on screening
    4. Complete Left bundle branch block, bifascicular block
    5. Any clinically significant ST segment and/or T-wave abnormalities
    6. Presence of unstable atrial fibrillation (ventricular response rate >100 bpm). Patients with stable atrial fibrillation can be enrolled provided they do not meet other cardiac exclusion criteria.
    7. Symptomatic congestive heart failure ( class III-IV)
  • Impairment of GI function or GI disease that may significantly alter the absorption of PANOBINOSTAT or RUXOLITINIB
  • Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol
  • Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug
  • Concomitant use of inhibitors
  • Patients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies.
  • Chemotherapy within 3 weeks prior to screening are excluded (other than hydroxyurea at stable doses and will be discontinued 24 hours prior to starting study drug).
  • Patients with an active bleeding tendency or are receiving any treatment with therapeutic doses of sodium warfarin (Coumadin®) or coumadin derivatives. Patients will be allowed to enter study on aspirin at doses of 81mg/d.
  • Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  • Women who are pregnant or breast-feeding or women of (WOCBP) not using an effective method of . WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential must have a negative serum pregnancy test within 24hrs of receiving the first dose of study medication.
  • Male patients whose sexual partners are WOCBP not using effective birth control
  • Patients with a prior within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
  • Disease associated with secondary MF such as carcinoma, lymphoma, myelodysplasia, hairy cell leukemia, mast cell disease or acute leukemia (including M7 disease or acute panmyelosis with MF)
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Panobinostat and Ruxolitinib

    Combination of Panobinostat and Ruxolitinib

    Drug: Panobinostat · Drug: Ruxolitinib

Interventions

  • PO TIW QOW or PO TIW QW

    Also known as: LBH589

  • PO BID x 28 days

    Also known as: INCB424, Jakafi

06

What researchers measure

Primary outcomes

  1. Number of Patients That Achieve Stable Disease or Clinical Improvement

    Number of patients that have either stable disease or clinical improvement treatment response as defined by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Stable disease (SD) - response that is not complete remission, partial remission, clinical improvement, anemia response, spleen response, symptoms response, or progressive disease. Clinical improvement (CI) - a response in anemia, splenomegaly, or MF-SB that is not associated with progressive splenomegaly or increase in severity of anemia, thrombocytopenia, or neutropenia.

    Time frame: at least 6 months

  2. Number of Participants Who Experienced Dose-Limiting (DLTs)

    Panobinostat related adverse events requiring dose reduction or discontinuing prior to Cycle 6, Day 29 (C6D29)

    Time frame: up to cycle 6, day 29

Secondary outcomes

  1. Percent Change in Spleen Volume

    Percent change in spleen volume at C6D29 as compared to baseline

    Time frame: Baseline and Cycle 6, Day 29

  2. Percent Change in Spleen Size for Responders and Non-responders

    Percent change in spleen length size by palpation at cycle 6, day 29 (C6D29) from baseline

    Time frame: Cycle 6, Day 29

  3. Percent Change in Spleen Length

    Percent change in spleen length at C6D29

    Time frame: Cycle 6, Day 29

  4. Number of Participants With Percent Change on Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)

    Symptom responders defined as having a percent change in MPN-SAF score from Screening/C1D1 to C6D29 of more than 50%.MPN-SAF is an 18-item instrument. Each item score 0-10 averaged, total scale from0-10, with higher score indicating more symptoms.

    Time frame: baseline, C1D1 and Cycle 6 Day 29

07

Results

Posted Oct 31, 2023

Participant flow

Cohort 1
Participant flow — Cohort 1
MilestonePanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
Started3000
Completed3000
Not completed0000
Cohort 2
Participant flow — Cohort 2
MilestonePanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
Started0600
Completed0600
Not completed0000
Cohort 3
Participant flow — Cohort 3
MilestonePanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
Started0030
Completed0030
Not completed0000
Cohort 4
Participant flow — Cohort 4
MilestonePanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
Started0003
Completed0003
Not completed0000

Outcome measures

PrimaryNumber of Patients That Achieve Stable Disease or Clinical Improvement

Number of patients that have either stable disease or clinical improvement treatment response as defined by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Stable disease (SD) - response that is not complete remission, partial remission, clinical improvement, anemia response, spleen response, symptoms response, or progressive disease. Clinical improvement (CI) - a response in anemia, splenomegaly, or MF-SB that is not associated with progressive splenomegaly or increase in severity of anemia, thrombocytopenia, or neutropenia.

Time frame:
at least 6 months
Reported as:
Count of participants · Participants
Number of Patients That Achieve Stable Disease or Clinical Improvement
ParticipantsPanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
Stable disease3413
Clinical Improvement0120
No response evaluated0100
PrimaryNumber of Participants Who Experienced Dose-Limiting (DLTs)

Panobinostat related adverse events requiring dose reduction or discontinuing prior to Cycle 6, Day 29 (C6D29)

Time frame:
up to cycle 6, day 29
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Dose-Limiting (DLTs)
ParticipantsPanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
requiring Panaobinostat dose reduction1031
Discontinuing Panobinostat0200
SecondaryPercent Change in Spleen Volume

Percent change in spleen volume at C6D29 as compared to baseline

Time frame:
Baseline and Cycle 6, Day 29
Reported as:
Median · percent change
Percent Change in Spleen Volume
percent changePanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
Percent Change in Spleen Volume-41 (-44 to -8)-8 (-61 to 25)-40 (-59 to 4)-17 (-29 to -15)
SecondaryPercent Change in Spleen Size for Responders and Non-responders

Percent change in spleen length size by palpation at cycle 6, day 29 (C6D29) from baseline

Time frame:
Cycle 6, Day 29
Reported as:
Median · percent change
Percent Change in Spleen Size for Responders and Non-responders
percent changeRespondersNon-Responders
Percent Change in Spleen Size for Responders and Non-responders-100 (-100 to -14)-29 (-100 to 0)
SecondaryPercent Change in Spleen Length

Percent change in spleen length at C6D29

Time frame:
Cycle 6, Day 29
Reported as:
Median · percent change
Percent Change in Spleen Length
percent changePanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
Percent Change in Spleen Length-83 (-100 to -29)-17 (-100 to 0)-14 (-100 to 0)-31 (-33 to -29)
SecondaryNumber of Participants With Percent Change on Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)

Symptom responders defined as having a percent change in MPN-SAF score from Screening/C1D1 to C6D29 of more than 50%.MPN-SAF is an 18-item instrument. Each item score 0-10 averaged, total scale from0-10, with higher score indicating more symptoms.

Time frame:
baseline, C1D1 and Cycle 6 Day 29
Reported as:
Count of participants · Participants
Number of Participants With Percent Change on Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)
ParticipantsPanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
Number of Participants With Percent Change on Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)1200

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panobinostat and Ruxolitinib Cohort 10/3 (0%)1/3 (33.3%)3/3 (100%)
Panobinostat and Ruxolitinib Cohort 20/6 (0%)2/6 (33.3%)6/6 (100%)
Panobinostat and Ruxolitinib Cohort 30/3 (0%)3/3 (100%)3/3 (100%)
Panobinostat and Ruxolitinib Cohort 40/3 (0%)0/3 (0%)3/3 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
AnemiaBlood and lymphatic system disorders1/32/62/30/3
FatigueGeneral disorders0/30/61/30/3
Night SweatsGeneral disorders0/30/61/30/3
HypertensionVascular disorders1/32/60/30/3
VomitingGastrointestinal disorders1/30/60/30/3
PneumoniaRespiratory, thoracic and mediastinal disorders0/30/61/30/3
Upper Respiratory InfectionRespiratory, thoracic and mediastinal disorders1/30/60/30/3
Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/32/60/30/3
Atrial fibrillationCardiac disorders0/30/61/30/3
FeverGeneral disorders0/30/61/30/3
Most frequent other events
Showing 10 of 75
Most frequent other events
EventPanobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4
DiarrheaGastrointestinal disorders3/33/62/32/3
DysphagiaNervous system disorders0/30/63/30/3
AnemiaBlood and lymphatic system disorders1/32/62/32/3
Upper Respiratory InfectionInfections and infestations1/34/62/31/3
HeadacheNervous system disorders1/32/60/32/3
Abdominal painGastrointestinal disorders2/31/61/30/3
FlatulenceGastrointestinal disorders1/30/61/32/3
Back PainMusculoskeletal and connective tissue disorders1/31/62/30/3
DysuriaRenal and urinary disorders2/30/60/30/3
Gastroesophageal RefluxGastrointestinal disorders2/30/60/30/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4Total
Median60 (53 to 74)61 (52 to 78)69 (46 to 78)64 (64 to 66)64 (46 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Panobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4Total
Female11114
Male252211
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Panobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4Total
Count of participants————0
Disease subtype
Disease subtype(Participants)Panobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4Total
Primary myelofibrosis (PMF)13116
Post essential thrombocythemia PET-MF23117
Post polycythemia vera PPV-MF00112
DIPSS Score
DIPSS Score(Participants)Panobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4Total
low (score 0)10001
intermediate-1 (score 1 or 2)02316
intermediate-2 (score 3 or 4)24028
JAK2^V617F positive
JAK2^V617F positive(Participants)Panobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4Total
Count of participants342110
Cytogenetics
Cytogenetics(Participants)Panobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4Total
Unfavorable Karyotype02002
Not Unfavorable Karyotype143311
Not available20002
Prior Myelofibrous (MF) Directed Therapy
Prior Myelofibrous (MF) Directed Therapy(Participants)Panobinostat and Ruxolitinib Cohort 1Panobinostat and Ruxolitinib Cohort 2Panobinostat and Ruxolitinib Cohort 3Panobinostat and Ruxolitinib Cohort 4Total
Count of participants262111

9 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
09

References and documents

Publications

  • Mascarenhas J, Marcellino BK, Lu M, Kremyanskaya M, Fabris F, Sandy L, Mehrotra M, Houldsworth J, Najfeld V, El Jamal S, Petersen B, Moshier E, Hoffman R. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF). Leuk Res. 2020 Jan;88:106272. doi: 10.1016/j.leukres.2019.106272. Epub 2019 Nov 16. PubMed 31778911 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of May 2018 and a completion of May 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2023, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2012
First posted
Sep 26, 2012
Start
Jan 2013
Primary completionActual
May 18, 2018
CompletionActual
May 18, 2018
Results first posted
Oct 31, 2023
Last update
Oct 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01693601
Lead sponsor
John Mascarenhas
Responsible party
John Mascarenhas (Associate Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Sep 26, 2012
Start date
Jan 2013
Primary completion
May 18, 2018
Completion
May 18, 2018
Results posted
Oct 31, 2023
Last update
Oct 31, 2023

Study contacts

John Mascarenhas, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Panobinostat · Ruxolitinib

Start the discussion